Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06395805 | Evaluation of Quality of Life and Self-assurance and Social Support Earned for Non-cellular Head Cancer | unknown | — | 100 | Andrzej Frycz Modrzewski Krakow UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04557020 | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC | unknown | Phase 3 | 200 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05858385 | Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients | unknown | — | 700 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06032663 | Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications | unknown | N/A | 10 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03757637 | Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients | unknown | N/A | 380 | National Taiwan University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05747365 | Role of Endocrine Disruptors in Thyroid Cancer(THY-ED) | unknown | — | 222 | Istituto Auxologico ItalianoOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06365866 | Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer. | unknown | N/A | 20 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04787939 | Early Feeding After Oral Cavity Reconstruction | unknown | N/A | 89 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06268600 | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma | unknown | N/A | 320 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03427827 | PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma(DIPPER) | unknown | Phase 3 | 450 | Sun Yat-sen UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06203808 | Impact in Head and Neck Oncology of Support by a Nurse in the Patient's Care Pathway(COACH-ORL) | unknown | — | 320 | University Hospital, ToulouseOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06341985 | DOsimetry and Radiation Induced NAusea in Head and Neck Cancers(DORIAN) | unknown | — | 180 | European Institute of OncologyOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06327139 | Optimising Patient Experience in Head and Neck Radiotherapy(OPEN) | unknown | Phase 3 | 201 | Irish Research Radiation Oncology GroupNETWORK | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05400239 | SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome | unknown | — | 60 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06156020 | Outcome Analysis of Endoscopic Resection of Pituitary Adenomas | unknown | N/A | 500 | National Cheng-Kung University HospitalOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT03024489 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 27 | Mahidol UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04354324 | Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma | unknown | N/A | 254 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06308796 | Prevention of Caries in Head and Neck Cancer Survivors Who Underwent Radiotherapy(RADIOCARIES) | unknown | N/A | 40 | University of MilanOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06308016 | Study of the Risk of Pharyngocutaneous Fistula in a Population of Patients Undergoing Total Laryngectomy and Creation of a Score for Pre-operative Risk Stratification. | unknown | — | 500 | Regina Elena Cancer InstituteOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06097793 | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | unknown | Early Phase 1 | 12 | Kousai Bio Co., Ltd.OTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06206681 | Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors | unknown | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04597476 | A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck | unknown | Phase 2 | 119 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04879654 | Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery(SNMM) | unknown | Phase 2 | 45 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT05156177 | Correlation of Fecal Microbiome and Its Metabolites With Outcome of Radiotherapy in Head and Neck Carcinoma(COMRAD-HNSCC) | unknown | — | 40 | Institute of Oncology LjubljanaOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06094985 | Prognostic Markers for a Better Follow-up in Head and Neck Cancer. | unknown | — | 20 | Karolinska InstitutetOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT05482841 | Lung Ultrasound Score After ENT Cancer Surgery(LUSENT) | unknown | — | 80 | Centre Leon BerardOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06272617 | Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer | unknown | N/A | 138 | West China HospitalOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT04671862 | Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis | unknown | N/A | 25 | Ottawa Hospital Research InstituteOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06269731 | Anxiety & Depression in Thyroid Cancer Patients | unknown | — | 159 | Assiut UniversityOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT05364411 | HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC(HYDRA) | unknown | N/A | 100 | Joris B.W. ElbersOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05860335 | Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06264778 | Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma | unknown | Phase 3 | 10 | Shandong UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01819480 | Efficacy and Safety of TORS for SCCA | unknown | N/A | 110 | Katherine L FedderOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05893810 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | unknown | Phase 3 | 176 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06234553 | Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma(RIPA) | unknown | — | 200 | Beijing Tiantan HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05385926 | Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 34 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06235918 | Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Xiang LuOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2024source: clinicaltrials